Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of Gammalinolenic Acid for Juvenile Rheumatoid Arthritis
This study has been completed.
Study NCT00004420   Information provided by FDA Office of Orphan Products Development
First Received: October 18, 1999   Last Updated: June 23, 2005   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Juvenile Rheumatoid Arthritis
Additional conditions recognized in this trial
Arthritis
Arthritis, Juvenile Rheumatoid
Arthritis, Rheumatoid
More general conditions related to this trial
Autoimmune Diseases
Connective Tissue Diseases
Immune System Diseases
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Interventions listed in this trial
gamma-Linolenic acid
Additional drug interventions recognized in this trial
Efamol
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antilipemic Agents
Antimetabolites
Antirheumatic Agents
Central Nervous System Agents
Dermatologic Agents
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
FDA Office of Orphan Products Development
University of Massachusetts


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services